



Supplemental Figure 1



Diabetes suppresses angiogenesis in a TNF dependent manner. **A:** Immunofluorescent images with anti-CD34 antibody or matched control antibody from 16 day normoglycemic fracture specimens in areas of endochondral bone formation with or without DAPI nuclear stain (200X magnification). **B:** Immunofluorescent images with anti-CD34 antibody from 16 day fracture specimens from areas of endochondral bone formation from normoglycemic, diabetic and diabetic mice treated TNF α -specific inhibitor (Pegsunercept) (400X or 100X magnification).


Supplemental Figure 2




Diabetes decreases VEGFA expression in hypertrophic chondrocytes in a TNF dependent manner. **A:** Immunofluorescent images with anti-VEGFA IgG or matched control IgG sections from 16 day normoglycemic fracture specimens containing both cartilage and bone with or without DAPI nuclear staining (200X magnification). **B:** Immunofluorescent images with anti-VEGFA IgG from 16 day fracture specimens containing hypertrophic chondrocytes from normoglycemic, diabetic and diabetic mice treated TNF α -specific inhibitor (Pegsunercept) (400X magnification).

Supplemental Figure 3

A



B



siRNA reduces FOXO1 expression. Human microvascular endothelial cells without (no treatment, NT) or with transfection with scrambled siRNA (siScr) or FOXO1 siRNA (siFOXO1) were examined for FOXO1 expression. **A.** FOXO1 mRNA levels were quantified by real-time PCR. **B.** FOXO1 protein level was quantified by immunofluorescence with specific FOXO1 antibody and presented as mean fluorescence intensity (MFI) per cell. Matched control antibody was negative.